Invesco Ltd. Ab Cellera Biologics Inc. Transaction History

Invesco Ltd.

$557 Billion
Q2 2025

A detailed history of Invesco Ltd. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Invesco Ltd. holds 37,112 shares of ABCL stock, worth $217,476. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,112

Previous 24,146 53.7%

Holding current value

$217,476

Previous $53,000 139.62%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$1.93 - $3.8 $25,024 - $49,270	12,966 Added 53.7%	37,112 $127,000
Q1 2025 May 12, 2025	BUY	$2.2 - $3.53 $28,364 - $45,512	12,893 Added 114.57%	24,146 $53,000
Q4 2024 Feb 13, 2025	BUY	$2.48 - $3.15 $751 - $954	303 Added 2.77%	11,253 $32,000
Q3 2024 Nov 12, 2024	SELL	$2.39 - $3.49 $6,675 - $9,747	-2,793 Reduced 20.32%	10,950 $28,000
Q2 2024 Aug 13, 2024	BUY	$2.73 - $4.73 $6,319 - $10,949	2,315 Added 20.26%	13,743 $40,000
Q1 2024 May 14, 2024	BUY	$4.29 - $5.97 $49,026 - $68,225	11,428 New	11,428 $51,000
Q1 2023 May 12, 2023	BUY	$7.31 - $11.18 $124,394 - $190,250	17,017 Added 21.76%	95,208 $717,000
Q4 2022 Feb 13, 2023	SELL	$9.48 - $14.52 $36,621 - $56,090	-3,863 Reduced 4.71%	78,191 $792,000
Q3 2022 Nov 14, 2022	BUY	$9.2 - $13.68 $43,194 - $64,227	4,695 Added 6.07%	82,054 $812,000
Q2 2022 Aug 15, 2022	BUY	$5.72 - $10.65 $442,493 - $823,873	77,359 New	77,359 $824,000
Q4 2021 Feb 14, 2022	SELL	$12.99 - $17.73 $365,148 - $498,390	-28,110 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$14.85 - $21.34 $205,731 - $295,644	13,854 Added 97.18%	28,110 $563,000
Q2 2021 Aug 17, 2021	BUY	$20.19 - $34.17 $287,828 - $487,127	14,256 New	14,256 $314,000

Others Institutions Holding ABCL

# of Institutions

150

Shares Held

114M

Call Options Held

488K

Put Options Held

476K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $1.67B
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account